The U.S. Supreme Court convened on Monday to deliberate a contentious case involving the Food and Drug Administration’s decision to deny two companies’ requests to market flavored e-liquids for e-cigarettes. The FDA’s rejections centered on concerns about the potential appeal of these products to young people, citing the risk of addiction and subsequent tobacco use. For additional context, the original coverage can be found on SCOTUSblog.
Triton Distribution and Vapetasia, the manufacturers at the heart of this legal challenge, argued that the FDA’s rejection was a significant departure from its prior stance. They had sought approval to market flavors such as “Rainbow Road” and “Crème Brulee,” yet found themselves opposed by the FDA’s assertion that there was insufficient evidence to demonstrate a benefit to adult smokers. The agency posited that flavored e-cigarettes primarily increase youth consumption.
Representing the FDA, Deputy Solicitor General Curtis Gannon contended that the applicants had failed to provide adequate scientific evidence showing that these flavors would facilitate a reduction in conventional cigarette use among adults. He emphasized that the decision to reject was based on the failure to prove this benefit strongly outweighs the risks to young people, as noted in a more detailed analysis provided by Johns Hopkins Medicine.
During the proceedings, Justice Clarence Thomas and other members of the Court questioned the transparency and consistency of the FDA’s guidance to the companies. The dialogue revealed underlying tensions around regulatory changes and the process of evaluating evidence submitted by companies. While some justices appeared sympathetic to the FDA’s position, others, like Justice Samuel Alito, scrutinized the level of evidence required.
The U.S. Court of Appeals for the 5th Circuit previously ruled in favor of the vape companies, suggesting the FDA executed a “regulatory switcheroo.” This ruling prompted discussions about whether the FDA had created new requirements unexpectedly.
As the arguments unfolded, the Justices deliberated on whether the case should be returned to the FDA for reconsideration, a common practice when regulatory mistakes are identified, as discussed by Chief Justice John Roberts. Justice Amy Coney Barrett questioned whether procedural fairness necessitated such a remand, despite a high probability that the FDA would maintain its stance.
The decision, pending the Justices’ review, could have significant implications for both public health policy and regulatory processes concerning the marketing of e-cigarettes in the United States.